Back to results
US 6,537,552 B1Granted
Vaccine adjuvant
AssigneeIowa State University Research Foundation, Inc.
InventorsF. Chris Minion, Sreekumar A. Menon, Gregory G. Mahairas
Life of this patent
Estimating the term…
Abstract
The invention features fusion agents such as fusion proteins that are useful for the treatment of and prevention from diseases that are susceptible to the effects of cellular (Th1 type) immune responses. Also encompassed by the invention are nucleic acids encoding the fusion proteins of the invention, vectors containing the nucleic acids, and cells containing the vectors. The invention includes methods of making and using the fusion agents of the invention.
Claims8
A fusion agent comprising a first domain and a second domain, wherein
- (a) the first domain comprises an immune enhancing molecule:
- and
- (b) the second domain comprises an immunogenic molecule, wherein the immunogenic molecule is a tumor antigen, an autoantigen, a molecule produced by a fungus, a molecule produced by a mycoplasma, a molecule produced by a yeast, a polypeptide encoded by a virus, or a molecule produced by a bacterium, wherein the bacterium is selected from the group consisting of Salmonella enteriditis, Listeria monocytogenes, Mycobacteria leprae, Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Borrelia burgdorferi, Actinobacillus pleuropneumoniae, Helicobacter pylori, Neisseria meningitidis, Yersinia eneterocolitica, Bordetella pertussis, and Porphyromonas gingivalis.
Dependencies are inferred from the claim text.